Short ragweed pollen allergen (Amb a 1 and related proteins) (Amb a 1 (for the major allergen); other allergens include Amb a 5, Amb a 6, Amb a 8, Amb a 10, and Amb a 11)

Short ragweed pollen allergen refers primarily to proteins derived from the pollen of *Ambrosia artemisiifolia* that trigger strong IgE-mediated allergic responses. The most clinically significant component is Amb a 1, also known as Antigen E, which is used as the reference standard for standardized extracts. Other important allergens include Amb a 5, Amb a 6 (a non-specific lipid transfer protein), Amb a 8, Amb a 10, and Amb a 11—the latter being recently characterized as belonging to the cysteine protease family with potent pro-inflammatory activity due to its enzymatic function. These molecules are not classical receptors but act as exogenous antigens that bind directly to human IgE antibodies on mast cells and basophils, triggering degranulation and release of histamine and other mediators responsible for allergy symptoms. They play no physiological role in humans but are central targets for both diagnosis—via skin prick tests or serum specific-IgE assays—and treatment through desensitization protocols using standardized extracts. The main therapeutic challenge is balancing effective desensitization with safety concerns regarding potential systemic allergic reactions during treatment initiation or escalation phases. Monitoring patient-specific biomarkers such as serum specific-IgE levels can help guide therapy decisions.

Other names

Short ragweed pollen antigenRagweed pollen allergenAntigen E (specifically for Amb a 1)Ragwitek (commercial extract name)

For drugs targeting this molecule/receptor: - Induction of immune tolerance via gradual exposure to the allergen in controlled doses during immunotherapy; reduces IgE-mediated hypersensitivity reactions over time. - Diagnostic use via skin testing or in vitro IgE measurement to confirm sensitization to short ragweed pollen allergens.